Skip to main
ABVX

Abivax SA (ABVX) Stock Forecast & Price Target

Abivax SA (ABVX) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 58%
Hold 0%
Sell 8%
Strong Sell 0%

Bulls say

Abivax is poised for success with their promising drug Obefazimod, which has the potential to become a first-line therapy for ulcerative colitis due to its strong results and potential for combination treatments. However, the company must address concerns about potential side effects and secure partnerships for development and commercialization, while also expanding into other indications to generate revenue and mitigate intellectual property risks. Despite these challenges, Abivax's potential success in the UC and CD market positions it as a strong investment opportunity.

Bears say

Abivax is currently facing a challenging landscape as it competes with established companies in the IBD market and has yet to successfully bring a drug to market. While its drug candidate, obefazimod, shows potential, there are significant safety concerns that may hinder its success. Additionally, the company's financials are not yet strong enough to support its ambitious R&D plans.

Abivax SA (ABVX) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 58% recommend Buy, 0% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abivax SA (ABVX) Forecast

Analysts have given Abivax SA (ABVX) a Buy based on their latest research and market trends.

According to 12 analysts, Abivax SA (ABVX) has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $136.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $136.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abivax SA (ABVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.